Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Efruxifermin in Metabolic Dysfunction Associated Steatohepatitis: NCT06215716 Clinical Landscape Report 2026
15 October 2026
NCT06215716 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Sintilimab in Recurrent Glioblastoma: NCT06220552 Clinical Landscape Report 2026
15 October 2026
NCT06220552 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06218524 Clinical Landscape Report 2026
15 October 2026
NCT06218524 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Glucagon in Metabolic Dysfunction Associated Steatohepatitis: NCT06240039 Clinical Landscape Report 2026
15 October 2026
NCT06240039 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Darifenacin Hydrobromide in Amyotrophic Lateral Sclerosis: NCT06249867 Clinical Landscape Report 2026
15 October 2026
NCT06249867 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma, IDH-Wildtype: NCT06258018 Clinical Landscape Report 2026
15 October 2026
NCT06258018 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vocimagene amiretrorepvec in High grade glioma: NCT06264388 Clinical Landscape Report 2026
15 October 2026
NCT06264388 clinical landscape for High grade glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mercaptopurine in Recurrent Glioblastoma: NCT06279767 Clinical Landscape Report 2026
15 October 2026
NCT06279767 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06297512 Clinical Landscape Report 2026
15 October 2026
NCT06297512 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
J2H-1702 in Metabolic Dysfunction Associated Steatohepatitis: NCT06297434 Clinical Landscape Report 2026
15 October 2026
NCT06297434 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
COYA-302 in Amyotrophic Lateral Sclerosis: NCT06307301 Clinical Landscape Report 2026
15 October 2026
NCT06307301 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Esomeprazole Magnesium in Metabolic Dysfunction Associated Steatohepatitis: NCT06302049 Clinical Landscape Report 2026
15 October 2026
NCT06302049 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…